U.S. markets open in 4 hours 41 minutes

TCR2 Therapeutics Inc. (TCRR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.99-0.30 (-3.23%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close9.29
Open9.26
Bid0.00 x 800
Ask0.00 x 1100
Day's Range8.94 - 9.48
52 Week Range8.94 - 35.86
Volume1,044,488
Avg. Volume541,436
Market Cap343.385M
Beta (5Y Monthly)2.09
PE Ratio (TTM)N/A
EPS (TTM)-2.34
Earnings DateNov 10, 2021 - Nov 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est34.20
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • TCR2 Therapeutics Inc.
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion. Pfizer also spends a leading amount on research and development, close to $8 billion annually. While Pfizer historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
    Rating
    Fair Value
    Economic Moat
    7 days agoMorningstar
View more
  • Benzinga

    Mid-Afternoon Market Update: Nasdaq Down 1%; Protagonist Therapeutics Shares Plummet

    Toward the end of trading Friday, the Dow traded down 0.47% to 4,587.22 while the NASDAQ fell 1.05% to 15,023.11. The S&P also fell, dropping 0.85% to 4,435.65. The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 41,788,110 cases with around 670,020 deaths. India confirmed a total of at least 33,381,720 cases and 444,240 deaths, while Brazil reported over 21,069,010 COVID-19 cases with 589,240 deaths. In total, there were at least 227,118,470 cases

  • Benzinga

    TCR2 Therapeutics Stock Plunges On Safety Signals From Gavo-cel Solid Tumor Trial

    TCR2 Therapeutics Inc (NASDAQ: TCRR) stock dropped to a 52-week low after interim results from the ongoing Phase 1 portion of the gavo-cel Phase 1/2 trial for mesothelin-expressing solid tumors. The data will be at the European Society for Medical Oncology (ESMO21) Congress 2021. Gavo-cel was administered up to dose level 5 (DL5) (5x108/m2 following lymphodepletion). Two dose-limiting toxicities were reported. One Grade 3 pneumonitis at DL1, which was resolved with supportive measures, and dose

  • Benzinga

    Mid-Morning Market Update: Markets Down; US Consumer Sentiment Edges Higher

    Following the market opening Friday, the Dow traded down 0.37% to 34,622.25 while the NASDAQ fell 0.58% to 15,094.19. The S&P also fell, dropping 0.55% to 4,449.03. The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 41,788,110 cases with around 670,020 deaths. India confirmed a total of at least 33,381,720 cases and 444,240 deaths, while Brazil reported over 21,069,010 COVID-19 cases with 589,240 deaths. In total, there were at least 227,118,470 ca